Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK
| Autor: | Markus Sellinger, Gero Neupert, Carolin Tonus |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Colorectal cancer Pyruvate Kinase Colonoscopy Tumor M2-PK Sensitivity and Specificity Letters To The Editor Feces Internal medicine Biomarkers Tumor medicine Humans Mass Screening Stage (cooking) Mass screening Aged medicine.diagnostic_test business.industry Gastroenterology General Medicine Middle Aged medicine.disease Gene Expression Regulation Neoplastic Colorectal cancer screening Biomarker (medicine) Female Colorectal Neoplasms business Rapid Communication |
| Popis: | AIM: To evaluate the utility of the innovative fecal tumor M2-Pyruvate kinase (M2-PK) test in our daily clinical routine, as a marker for the pre-selection of patients who should subsequently undergo colonoscopy for the diagnosis or exclusion of colorectal cancer. METHODS: Fecal tumor M2-PK was measured in stool samples of 96 study participants (33 patients with colorectal cancer, 21 patients with rectal carcinoma and 42 controls) who all underwent total colonoscopy. RESULTS: In 39 of 42 individuals in the control group, fecal tumor M2-PK was below 4.0 kU/L (93% specifi city). Colorectal tumors were accompanied by a highly significant increase (P < 0.001) in fecal tumor M2- PK levels (median: colon carcinoma, 23.1 kU/L; rectal carcinoma, 6.9 kU/L; colorectal carcinoma, 14.7 kU/L), which correlated with Duke's staging and T-classifi cation. The overall sensitivity was 78% for colorectal cancer, increasing from 60% for stage T1 to 100% for stage T4 and from 60% for Duke's A to 90% for Duke's D tumors. CONCLUSION: Fecal tumor M2-PK is an appropriately sensitive tool to pre-select those patients requiring colonoscopy for the further diagnostic confirmation or exclusion of colorectal cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|